Hepatic enhancement and signal intensity analysis on magnetic resonance imaging as prognostic biomarkers in advanced chronic liver disease

Table 12 Quantitative decision-curve analysis at prespecified thresholds (hepatic enhancement models vs reference model)¹

Endpoint	Horizon (months)	Added variable to reference model	Threshold	ΔNB (95%CI)	Net reduction per 100
Decompensation	12 months	+ HE global	0.10	-0.0020 (-0.0056; 0.001)	-2
	24 months	+ HE global	0.10	+0.0011 (0.000; 0.0033)	1
	24 months	+ HE global	0.20	+0.0100 (0.0025; 0.020)	4
Mortality	12 months	+ HE segment VI	0.10	+0.0110 (0.000; 0.032)	10
	12 months	+ HE global	0.10	+0.0120 (0.000; 0.033)	11
	12 months	+ HE global	0.20	+0.0225 (0.000; 0.055)	9
	24 months	+ HE global	0.10	+0.0067 (0.0011; 0.0133)	6

¹The reference model: Functional Liver Imaging Score + Model for End-Stage Liver Disease 3.0 + etiology + prior hepatocellular carcinoma status. ΔNB is the net-benefit gain vs the reference model. “Net reduction per 100” translates ΔNB into fewer unnecessary interventions per 100 patients at the same true-positive yield.

CI: Confidence interval; NB: Net benefit; HE: Hepatic enhancement.